Are you aware of the silent threat posed by RSV? This common respiratory virus can quickly escalate into a serious condition ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved the monoclonal antibody clesrovimab-cfor for preventing RSV disease in babies. Unlike ...

RSV is the leading cause of hospitalization for babies under one and can lead to severe respiratory issues. New FDA-approved immunizations have been shown to significantly reduce RSV-related ...

Immunization with the long-acting monoclonal antibody nirsevimab may provide stronger protection against hospitalizations for ...

RSV can present as mild, cold-like symptoms in many children, but it is the leading cause of hospitalization in babies under 1 year, and can lead to conditions like pneumonia and bronchiolitis. While ...

Credit: Merck Enflonsia is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody that is designed to provide durable protection through 5 months. The ACIP voted that Enflonsia ...

During the first RSV season in which a maternal vaccine and a monoclonal antibody for infants were available, 72% of infants were immunized, this study found. Disparities in access to immunization ...

Real-world data from Madrid hospitals show dramatic declines in infant ICU stays, hospital days, and RSV-related admissions after nirsevimab immunization campaign. Study: Impact of Nirsevimab on RSV ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants. The US Food and Drug Administration ...

Please provide your email address to receive an email when new articles are posted on . Nirsevimab and maternal vaccination produced strong increases in RSV neutralizing antibodies in infants.

Australia's new respiratory syncytial virus (RSV) immunization program cut hospital admissions for Australia's youngest ...